Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FTY720 Inhibits MPP+-Induced Microglial Activation by Affecting NLRP3 Inflammasome Activation
Yao Shu, Longjun Li, Xin Sun, et al.
Journal of Neuroimmune Pharmacology (2019) Vol. 14, Iss. 3, pp. 478-492
Closed Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases
Anguo Wu, Xiaogang Zhou, Gan Qiao, et al.
Ageing Research Reviews (2020) Vol. 65, pp. 101202-101202
Closed Access | Times Cited: 154
Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson’s Disease
Yunna Li, Yun Xia, Sijia Yin, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 107
Signaling pathways in macrophages: molecular mechanisms and therapeutic targets
Ming Li, Mengjie Wang, Yuanjia Wen, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 40
Microglia and macrophage phenotypes in intracerebral haemorrhage injury: therapeutic opportunities
Qian Bai, Mengzhou Xue, V. Wee Yong
Brain (2019) Vol. 143, Iss. 5, pp. 1297-1314
Open Access | Times Cited: 126
IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease
Zhan Liu, Ao-Wang Qiu, Yan Huang, et al.
Brain Behavior and Immunity (2019) Vol. 81, pp. 630-645
Closed Access | Times Cited: 124
Glutathione Depletion and Parkinsonian Neurotoxin MPP+-Induced TRPM2 Channel Activation Play Central Roles in Oxidative Cytotoxicity and Inflammation in Microglia
Kenan Yıldızhan, Mustafa Nazıroğlu
Molecular Neurobiology (2020) Vol. 57, Iss. 8, pp. 3508-3525
Closed Access | Times Cited: 73
NLRP3 Inflammasome Activation: A Therapeutic Target for Cerebral Ischemia–Reperfusion Injury
Lixia Wang, Wei Ren, Qing-Juan Wu, et al.
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 53
The PI3K-AKT pathway: A plausible therapeutic target in Parkinson's disease
Ahsas Goyal, Anant Agrawal, Aanchal Verma, et al.
Experimental and Molecular Pathology (2022) Vol. 129, pp. 104846-104846
Open Access | Times Cited: 53
Role of NLRP3 Inflammasome in Parkinson’s Disease and Therapeutic Considerations
Linh Thi Nhat Nguyen, Hữu Đạt Nguyễn, Yun Joong Kim, et al.
Journal of Parkinson s Disease (2022) Vol. 12, Iss. 7, pp. 2117-2133
Open Access | Times Cited: 39
Siponimod inhibits microglial inflammasome activation
Hiroyasu Komiya, Hideyuki Takeuchi, Akihiro Ogasawara, et al.
Neuroscience Research (2025)
Open Access
Key Mechanisms and Potential Targets of the NLRP3 Inflammasome in Neurodegenerative Diseases
Yadi Guan, Fang Han
Frontiers in Integrative Neuroscience (2020) Vol. 14
Open Access | Times Cited: 58
Berberine Protects Against NLRP3 Inflammasome via Ameliorating Autophagic Impairment in MPTP-Induced Parkinson’s Disease Model
Shuxuan Huang, Hanqun Liu, Yuwan Lin, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 50
Crosstalk Between the NLRP3 Inflammasome/ASC Speck and Amyloid Protein Aggregates Drives Disease Progression in Alzheimer’s and Parkinson’s Disease
Jonathan Hulse, Kiran Bhaskar
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 32
Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod
Safura Pournajaf, Leila Dargahi, Mohammad Javan, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 31
Echinacoside Protects Dopaminergic Neurons Through Regulating IL-6/JAK2/STAT3 Pathway in Parkinson’s Disease Model
Xueping Yang, Qingyun Yv, Fanlong Ye, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 27
Fingolimod suppressed the chronic unpredictable mild stress-induced depressive-like behaviors via affecting microglial and NLRP3 inflammasome activation
Yuanxin Guo, Xiaohong Tracey Gan, Houfeng Zhou, et al.
Life Sciences (2020) Vol. 263, pp. 118582-118582
Closed Access | Times Cited: 47
Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
Pablo Bascuñana, Luisa Möhle, Mirjam Brackhan, et al.
Drugs in R&D (2020) Vol. 20, Iss. 3, pp. 197-207
Open Access | Times Cited: 40
Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson′s disease
Haiyang Yu, Tong Sun, Zhen Wang, et al.
Neural Regeneration Research (2022)
Open Access | Times Cited: 24
Investigating Therapeutic Effects of Indole Derivatives Targeting Inflammation and Oxidative Stress in Neurotoxin-Induced Cell and Mouse Models of Parkinson’s Disease
Ya‐Jen Chiu, Chih‐Hsin Lin, Chung‐Yin Lin, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2642-2642
Open Access | Times Cited: 14
Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure
Sunny Malhotra, Laura Hurtado‐Navarro, Agustín Pappolla, et al.
Neurology Neuroimmunology & Neuroinflammation (2023) Vol. 10, Iss. 3
Open Access | Times Cited: 13
Therapeutic Potential of Fingolimod on Psychological Symptoms and Cognitive Function in Neuropsychiatric and Neurological Disorders
Fatemeh Rahmati‐Dehkordi, Hadi Khanifar, Nazanin Najari, et al.
Neurochemical Research (2024) Vol. 49, Iss. 10, pp. 2668-2681
Closed Access | Times Cited: 3
The BRCC3 regulated by Cdk5 promotes the activation of neuronal NLRP3 inflammasome in Parkinson’s disease models
Xinyu Cheng, Shaoye Xu, Conghui Zhang, et al.
Biochemical and Biophysical Research Communications (2019) Vol. 522, Iss. 3, pp. 647-654
Closed Access | Times Cited: 30
Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System
Kim M. A. De Kleijn, Gerard J.M. Martens
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 12, pp. 4229-4229
Open Access | Times Cited: 30
Ameliorative effects of Fingolimod (FTY720) on microglial activation and psychosis-related behavior in short term cuprizone exposed mice
Siyao Li, Koki Sakurai, Masahiro Ohgidani, et al.
Molecular Brain (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 9
The interplay between α-Synuclein and NLRP3 inflammasome in Parkinson's disease
Qianhui Huang, Pei Yang, Yang Liu, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115735-115735
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top